Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The Parkinson’s disease drugs market was valued at USD 5.76 Billion in 2025. It is poised to grow at a CAGR of 3.58% during the forecast period of 2026-2035, and reach USD 8.19 Billion by 2035. The market growth is driven by rising Parkinson’s prevalence, increasing adoption of carbidopa–levodopa and dopamine agonists, expanding geriatric population, and advancements in oral and injectable formulations enhancing patient compliance and therapeutic outcomes.
Key Market Trends and Insights
- Based on drug class, carbidopa/levodopa accounted for over 35% of the market share in the historical period.
- Oral formulations represented approximately 75% of the market by route of administration in the historical period.
- By region, the United States dominated the market, capturing around 41% of market share in the historical period.
Market Size and Forecast
- Market Size (2025): USD 5.76 Billion
- Projected Market Size (2035): USD 8.19 Billion
- CAGR (2026-2035): 3.58%
Compound Annual Growth Rate
3.58%
Value in USD Billion
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Parkinson’s Disease Drugs Market Overview
The market is expanding steadily, driven by the increasing prevalence of Parkinson’s, an aging global population, and growing awareness of early diagnosis. Oral formulations dominate, with carbidopa/levodopa remaining the most prescribed therapy. The market growth is supported by innovations in drug delivery, improved patient adherence, and rising adoption of advanced treatment options across developed and emerging regions. The market reached a value of approximately USD 5.76 Billion in 2025.
Parkinson’s Disease Drugs Market Growth Drivers
Regulatory Approvals for Subcutaneous Dopamine Agonists Boosting the Market Expansion
Growing demand for advanced-stage management and increasing regulatory support for innovative delivery technologies are propelling the market. For instance, in February 2025, Supernus Pharmaceuticals received FDA approval for Onapgo, the first subcutaneous continuous infusion dopamine agonist device for advanced Parkinson's disease. This milestone is projected to expand market reach and accelerate infusion-based formulation adoption through the forecast period.
Parkinson’s Disease Drugs Market Trends
Key trends shaping the market include increasing use of MAO-B inhibitors, rising geriatric population, technological advancements, and expanding access to innovative therapies globally.
Advancements in Subcutaneous Levodopa-Based Infusion Approvals Reshaping the Market Landscape
The rising prevalence of advanced-stage Parkinson's and demand for non-surgical symptom control are reshaping the market. Subcutaneous delivery innovations are overcoming oral formulation limitations. For instance, in October 2024, AbbVie received FDA approval for Vyalev, the first 24-hour subcutaneous levodopa-based infusion therapy for motor fluctuations in advanced Parkinson's disease, expected to redefine treatment paradigms and drive market expansion in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Parkinson’s Disease Drugs Market Segmentation
Market Breakup by Drug Class
- MAO-B Inhibitors
- Carbidopa/levodopa
- COMT Inhibitors
- Dopamine Agonists
- Anticholinergics
- Amantadine
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channel
Market Breakup by End User
- Hospital
- Specialty Clinics
- Homecare Settings
- Academic and Healthcare Settings
- Others
Market Breakup by Country
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Parkinson’s Disease Drugs Market Share
Oral Expected to Lead the Market Segment by Route Of Administration
Oral dominated the market segment by route of administration during the historical period, holding about 75% of the total market. These formulations remain preferred due to ease of use, consistent dosing, and improved patient adherence. Among therapies, carbidopa/levodopa continues to be the backbone of treatment, driving demand and supporting steady growth across global healthcare settings.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Parkinson’s Disease Drugs Market Analysis by Region
The United States led the market geographically during the historical period, capturing approximately 42% of the market. The market growth is supported by advanced healthcare infrastructure, early diagnosis initiatives, and high adoption of innovative therapies. In particular, dopamine agonist treatments are increasingly utilized to manage motor symptoms, reinforcing the region’s dominance in market share.
Leading Players in the Parkinson’s Disease Drugs Market
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic plc
Established in 1949, Medtronic plc is headquartered in Dublin, Ireland. In Parkinson’s Disease, it is recognized for deep brain stimulation systems that provide precise neuromodulation for motor symptom control. Medtronic also supports programmable implantable devices and patient monitoring platforms, aiming to enhance therapeutic outcomes and advance reserach in Parkinson’s disease-modifying management.
Pfizer, Inc.
Founded in 1849 and headquartered in New York, USA, Pfizer, Inc. develops therapies for neurological disorders, including Parkinson’s disease. The company’s portfolio features dopamine agonist medications that help manage motor symptoms. Pfizer continues research on disease-modifying therapies and adjunctive treatments to improve patient quality of life and reduce motor complications.
AbbVie Inc.
AbbVie Inc., founded in 2013 and based in North Chicago, USA, develops therapies addressing neurodegenerative conditions. In Parkinson’s Disease, AbbVie focuses on COMT inhibitors and dyskinesia management solutions. The company actively invests in clinical trials for novel disease-modifying therapies while providing supportive care options to enhance patient motor function and daily living activities.
GlaxoSmithKline plc.
Headquartered in London, UK, and founded in 2000 through a merger, GlaxoSmithKline plc. offers a range of Parkinson’s Disease therapies. Their portfolio includes MAO-B inhibitors that support symptom management and adjunctive care. GSK emphasizes research on innovative compounds targeting disease progression, as well as improving patient adherence and long-term treatment outcomes.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are Viatris, Teva Pharmaceutical Industries Ltd, H. Lundbeck A/S, Merck & Co., Inc., Supernus Pharmaceuticals, Inc., and Novartis AG.
Key Questions Answered in the Parkinson’s Disease Drugs Market
- What was the Parkinson’s disease drugs market value in 2025?
- What is the Parkinson’s disease drugs market forecast outlook for 2026-2035?
- What major factors aid the demand for Parkinson’s disease drugs market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market’s major drivers, opportunities, and restraints?
- What are the major Parkinson’s disease drugs market trends?
- Which drug class is expected to dominate the market segment?
- Which route of administration is expected to dominate the market segment?
- Which distribution channel is expected to dominate the market segment?
- Which end user is expected to dominate the market segment?
- Who are the key players in the Parkinson’s disease drugs market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$3299 $2969
-
$5499 $4949
-
$6999 $5949
-
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
